This program will provide you with a sense of confidence in medical practice, which will help you grow personally and professionally”

A fundamental objective of the program is to bring students closer to and disseminate computer knowledge, which is already applied in other fields of knowledge, but has minimal implementation in the medical world, despite the fact that for genomic medicine to become a reality it is necessary to accurately interpret the huge volume of clinical information currently available and associate it with the biological data generated after a bioinformatic analysis. While this is a difficult challenge, it will allow the effects of genetic variation and potential therapies to be explored quickly, inexpensively and with greater precision than is currently possible.

Humans are not naturally equipped to perceive and interpret genomic sequences, to understand all the mechanisms, pathways and interactions that take place within a living cell, nor to make medical decisions with tens or hundreds of variables. To move forward, a system with superhuman analytical capabilities is required to simplify the work environment and show the relationships and proximities between variables. In genomics and biology, it is now recognized that it is better to spend resources on new computational techniques than on pure data collection, something that is possibly the same in medicine and, of course, oncology. 

We have millions of data or publications but when they are analyzed by physicians or biologists, the conclusions are totally subjective and relative to the available publications or data, which are prioritized arbitrarily. This generates partial knowledge, which is increasingly distanced from the genetic and biological knowledge available and supported by computation, so a giant step in the implementation of precision medicine is to reduce this distance through the massive analysis of available medical and pharmacological information.

Update your knowledge with the Postgraduate diploma in Clinical Application of Genomic Oncology"

This Postgraduate diploma in Clinical Application of Genomic Oncology contains the most complete and up-to-date scientific program on the market. Its most notable features are:

• Development of case studies presented by experts in Clinical Application of Genomic Oncology 
• Its graphic, schematic and eminently practical contents provide scientific and practical information on those disciplines that are essential for professional practice
• New developments on the clinical application of genomic oncology
• It contains practical exercises where the self-assessment process can be carried out to improve learning
• Special emphasis on innovative methodologies in Clinical Application of Genomic Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Postgraduate diploma may be the best investment you can make when selecting a refresher program, for two reasons: in addition to updating your knowledge in Clinical Application of Genomic Oncology, you will obtain a Postgraduate diploma from TECH Global University"

Its teaching staff includes professionals belonging to the field of clinical application of genomic oncology, who bring to this program the experience of their work, as well as renowned specialists belonging to reference societies and prestigious universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive program designed to learn in real situations.

This program is designed around Problem-Based Learning, whereby the students must try to solve the different professional practice situations that arise throughout the program. For this purpose, students will be assisted by an innovative, interactive video system created by renowned and experienced experts in the field of clinical application of genomic oncology with extensive teaching experience.

Increase your decision-making confidence by updating your knowledge through this Postgraduate diploma"

Take the opportunity to learn about the latest advances in the clinical application of genomic oncology and improve the care of your patients"

The structure of the contents has been designed by a team of professionals from the best hospitals and universities in Spain, aware of the relevance of current program to intervene in the clinical application of genomic oncology and committed to quality teaching through new educational technologies.

This Postgraduate diploma in Clinical Application of Genomic Oncology contains the most complete and up-to-date scientific program on the market”

Module 1. Molecular Biology 

1.1. Molecular Mechanisms of Cancer 

1.1.1. Cellular Cycle
1.1.2. Detachment of Tumor Cells

1.2. Reprogramming of the Tumor Microenvironment

1.2.1. The Tumor Microenvironment: An Overview
1.2.2. MSD as a Prognostic Factor in Lung Cancer
1.2.3. TME in the Progression and Metastasis of Lung Cancer

1.2.3.1. Cancer-Associated Fibroblasts (CAF)
1.2.3.2. Endothelial Cells
1.2.3.3. Hypoxia in Lung Cancer
1.2.3.4. Inflammation
1.2.3.5. Immune Cells

1.2.4. Contribution of TME to Therapeutic Resistance

1.2.4.1. Contribution of TME to Radiotherapy Resistance

1.2.5. TME as a Target Treatment in Lung Cancer

1.2.5.1. Future Directions

1.3. Tumor Immunology: The Bases of Immunotherapy in Cancer

1.3.1. Introduction to the Immune System
1.3.2. Tumor Immunology

1.3.2.1. Tumor-Associated Antigens
1.3.2.2. Identification of Tumor-Associated Antigens
1.3.2.3. Types of Tumor-Associated Antigens

1.3.3. The Bases of Immunotherapy in Cancer

1.3.3.1. Introduction to the Immunotherapeutic Approaches
1.3.3.2. Monoclonal Antibodies in Cancer Therapy

1.3.3.2.1. Production of Monoclonal Antibodies
1.3.3.2.2. Types of Therapeutic Antibodies
1.3.3.2.3. Mechanisms of Action of Antibodies
1.3.3.2.4. Modified Antibodies

1.3.4. Non-Specific Immune Modulators

1.3.4.1. Bacillus of Calmette-Guérin
1.3.4.2. Interferon-α
1.3.4.3. Interleucina-2
1.3.4.4. Imiquimod

1.3.5. Other Approaches for Immunotherapy

1.3.5.1. Dendritic Cell Vaccines
1.3.5.2. Sipuleucel-T
1.3.5.3. CTLA-4 Blocking
1.3.5.4. Adoptive T-cell Therapy

1.3.5.4.1. Adoptive Cell Therapy With T-cell Clones
1.3.5.4.2. Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes

1.4. Molecular Mechanisms Involved in the Invasion and Metastasis Process

Module 2. Genomic or Precision Oncology

2.1. Usefulness of Gene Expression Profiling in Cancer
2.2. Molecular Subtypes of Breast Cancer
2.3. Prognostic-Predictive Genomic Platforms in Breast Cancer
2.4. Therapeutic Targets in Non-Small Cell Lung Cancer

2.4.1. Introduction
2.4.2. Molecular Detection Techniques
2.4.3. EGFR Mutation
2.4.4. ALK Translocation
2.4.5. ROS Translocation
2.4.6. BRAF Mutation 
2.4.7. NRTK Rearrangements 
2.4.8. HER2 Mutation 
2.4.9. MET Mutation/Amplification
2.4.10. RET Rearrangements 
2.4.11. Other Molecular Targets

2.5. Molecular Classification of Colon Cancer
2.6. Molecular Studies in Gastric Cancer 

2.6.1. Treatment of Advanced Gastric Cancer
2.6.2. HER2 Overexpression in Advanced Gastric Cancer 
2.6.3. Identification and Interpretation of HER2 Overexpression in Advanced Gastric Cancer 
2.6.4. Drugs With Activity Against HER2
2.6.5. Trastuzumab in the First Line of Advanced Gastric Cancer 

2.6.5.1. Treatment of HER2+ Advanced Gastric Cancer After Progression to Trastuzumab-Based Regimens 

2.6.6. Activity of Other Anti-HER2 Drugs in Advanced Gastric Cancer 

2.7. GIST as a Model of Translational Research: 15 Years of Experience

2.7.1. Introduction
2.7.2. Mutations of KIT and PDGFRA as Major Promoters in GIST 
2.7.3. Genotype in GIST: Prognostic and Predictive Value 
2.7.4. Genotype in GIST and Resistance to imatinib
2.7.5.  Conclusions

2.8. Molecular and Genomic Biomarkers in Melanoma
2.9. Molecular Classification of Brain Tumors
2.10. Molecular and Genomic Biomarkers in Melanoma
2.11. Immunotherapy and Biomarkers

2.11.1. Landscape of Immunological Therapies in Cancer Treatment and the Need to Define the Mutational Profile of a Tumor
2.11.2. Checkpoint Inhibitor Biomarkers: PD-L1 and Beyond 

2.11.2.1. The Role of PD-L1 in Immune Regulation 
2.11.2.2. Clinical Trial Data and PD-L1 Biomarker
2.11.2.3. Thresholds and Assays for PD-L1 Expression: a Complex Picture
2.11.2.4. Budding Biomarkers

2.11.2.4.1. Tumor Mutational Burden (TMB) 

2.11.2.4.1.1. Quantification of the Tumor Mutational Burden
2.11.2.4.1.2. Evidence of the Tumor Mutational Burden
2.11.2.4.1.3. Burden as a Predictive Biomarker
2.11.2.4.1.4. Burden as a Prognosis Biomarker
2.11.2.4.1.5. The Future of the Mutational Burden

2.11.2.4.2. Microsatellite Instability
2.11.2.4.3. Immune Infiltrate Analysis
2.11.2.4.4. Toxicity Markers

2.11.2.5. Immune Checkpoint Drug Development in Cancer
2.11.2.6. Available Drugs

Module 3. Changes in Current Clinical Practice and New Applications With Genomic Oncology

3.1. Liquid Biopsies: Fashion or Future? 

3.1.1. Introduction
3.1.2. Circulating Tumor Cells
3.1.3. CtDNA
3.1.4. Clinical Applications
3.1.5. CtDNA Limitations
3.1.6. Conclusions and Future

3.2. Role of the Biobank in Clinical Research

3.2.1. Introduction
3.2.2. Is it Worth the Effort to Create a Biobank? 
3.2.3. How to Begin Establishing a Biobank
3.2.4. Informed Consent for the Biobank
3.2.5. Collecting Samples for the Biobank
3.2.6. Quality Control
3.2.7. Access to Samples

3.3. Clinical Trials: New Concepts Based on Precision Medicine

3.3.1. What Are Clinical Trials? What Sets Them Apart From Other Types of Research? 

3.3.1.1. Types of Clinical Trials

3.3.1.1.1. By Their Objectives
3.3.1.1.2. By The Number of Partaking Centers
3.3.1.1.3. By Their Methodology
3.3.1.1.4. By Their Level of Masking

3.3.2. Results of Clinical Trials in Thoracic Oncology

3.3.2.1. Related to Survival Time
3.3.2.2. Results Related to the Tumor
3.3.2.3. Results Notified by the Patient

3.3.3. Clinical Trials in the New Age of Precision Medicine

3.3.3.1. Precision Medicine
3.3.3.2. Terminology Relate to the Design of Trials in the Era of Precision Medicine

3.4. Incorporation of Actionable Markers in Clinical Practice
3.5. Application of Genomics in Clinical Practice by Type of Tumor
3.6. Decision Support Systems in Oncology Based on Artificial Intelligence

Module 4. Application of Bioinformatics in Genomic Oncology

4.1. Clinical and Pharmacological Enrichment of Gene Variants
4.2. Mass Search in PubMed for Genomic Information
4.3. Mass Search in DGIdb for Genomic Information
4.4. Mass Search in Clinical Trials for Clinical Trials on Genomic Data
4.5. Gene Similarity Search for the Interpretation of a Gene Panel or Exome
4.6. Mass Search for Genes Connected to a Disease
4.7. Enrich-Gen: Platform for the Clinical and Pharmacological Enrichment of Genes
4.8. Procedure to Produce a Genomic Report in the Age of Precision Oncology

A unique, key, and decisive training experience to boost your professional development”